Adicet Bio, Inc, under the ticker symbol ACET, recently published its fourth quarter financial reports. The figures show a decrease in losses compared to the same period last year. It has also met the average market expectations.
The reported losses for the biotech company stood at $29.49 million, which equates to $0.69 per share. When compared to last year's Q4, which had losses of $29.88 million or $0.72 a share, there is an improvement.
Analysts had predicted this level of loss, averaging their estimates at $0.69 per share. This data is compiled and made available by Thomson Reuters and typically does not include any extraordinary items.
A summary of GAAP (Generally Accepted Accounting Principles) results of Adicet Bio, Inc portrays a relatively consistent performance. Earnings for Q4 stood at -$29.49 million, compared to -$29.88 million of the previous year. The EPS (Earnings per Share) for Q4 was -$0.69, a slight improvement compared to last year's -$0.72.
